3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
7
Phase NA
5
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 3
1
Status
Completed
5
Not yet recruiting
3
Terminated
2
Recruiting
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
123
Breast Neoplasms
103
Neoplasms
100
Leukemia, Myeloid, Acute
88
Melanoma
84
Multiple Myeloma
81
Neoplasm Metastasis
80
Recurrence
68
Ovarian Neoplasms
65
Prostatic Neoplasms
59
Lymphoma
59
Colorectal Neoplasms
58
Lymphoma, Non-Hodgkin
55
Leukemia
55
Pancreatic Neoplasms
50
Lung Neoplasms
47
Leukemia, Lymphocytic, Chronic, B-Cell
42
Myelodysplastic Syndromes
41
Carcinoma, Renal Cell
39
Squamous Cell Carcinoma of Head and Neck
38
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Glioblastoma
35
Lymphoma, Large B-Cell, Diffuse
34
Triple Negative Breast Neoplasms
33
Carcinoma, Hepatocellular
33
Stomach Neoplasms
29
Small Cell Lung Carcinoma
27
Lymphoma, Follicular
27
Brain Neoplasms
26
Lymphoma, Mantle-Cell
25
Interventions
picropodophyllin
1
bempegaldesleukin
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Terminated
×
Ependymoma
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts